SynthesisIrish journal of medical science2014
Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis.
Synthesis in Irish journal of medical science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Differences in Glycemic Abnormalities Between Primary Aldosteronism and Essential Hypertension: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Metabolic risk factors for non-communicable diseases in Ethiopia: a systematic review and meta-analysis.BMJ open · 2021Pooled it
- Development and validation of a novel diagnostic nomogram model to predict primary aldosteronism in patients with hypertension.Endocrine · 2021Trial
- Association between primary aldosteronism and type 2 diabetes and identification of potential molecular mechanisms.Frontiers in endocrinology · 2026Article
- Evaluation of Predictive Risk Factors of Persistent Hypertension in Hyperaldosteronism After Surgery.International journal of endocrinology and metabolism · 2025Article
- Prevalence and impact of diabetes and prediabetes on presentation and complications of primary hyperaldosteronism at diagnosis.World journal of clinical cases · 2024Article
- Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry.Journal of endocrinological investigation · 2023Article
- Findings from the Indonesian family life survey on patterns and factors associated with multimorbidity.Scientific reports · 2023Article
- Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs.Metabolites · 2023Review
- Primary Aldosteronism: State-of-the-Art Review.American journal of hypertension · 2022Article
- Primary aldosteronism - a multidimensional syndrome.Nature reviews. Endocrinology · 2022Review
- The Relationship Between Renal Stones and Primary Aldosteronism.Frontiers in endocrinology · 2022Article
- Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism.Frontiers in endocrinology · 2022Review
- Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism.Endocrine · 2021Article
- Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.Frontiers in cardiovascular medicine · 2021Review
- Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.Endocrinology and metabolism (Seoul, Korea) · 2020Article
- MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism.European journal of endocrinology · 2020Review
- Primary Aldosteronism Diagnosis and Management: A Clinical Approach.Endocrinology and metabolism clinics of North America · 2019Review
- Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.Current cardiology reports · 2019Review
- Aldosterone stimulation mediates cardiac metabolism remodeling via Sirt1/AMPK signaling in canine model.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo conduct a meta-analysis of studies assessing abnormal glucose metabolism (AGM) prevalence among patients with primary aldosteronism (PA), calculating a combined pooled prevalence and summarizing metabolic parameters associated the pooled prevalence for comparative group.
methodFour electronic databases (PubMed, EMBASE, Cochrane CENTRAL, and ISI-Web of Science) were systematically retrieved with no language and time restriction. Studies about elevated level of glucose metabolism in primary aldosteronism were included.
resultData were available in 16 studies. The pooled analysis revealed that the prevalence of elevated glucose in PA was 22.41 % (95 % CI 16.77-28.05 %), the retrospectively calculated prevalence was 31.20 % (95 % CI 15.81-46.60 %) for impaired fasting glucose, 26.19 % (95 % CI 15.17-37.21 %) for impaired glucose tolerance, 15.22 % (95 % CI 9.93-20.51 %) for diabetes mellitus. Prevalence of AGM in PA was higher than that in essential hypertension (OR = 1.55, 95 % CI 1.01-2.36, p = 0.04). From comparative groups, patients with primary aldosteronism had a lower level of insulin sensitivity indicators in comparison with normal group (p < 0.01). On the other hand, insulin resistance which presented by HOMA index was stronger in PA group than in normal control group (WMD = 0.41, 95 % CI 0.17, 0.65; p = 0.001), whereas it was weaker than that in EH group (WMD = -0.37, 95 % CI -0.62, -0.13; p = 0.003).
conclusionThere is a significant prevalence of elevated level of glucose metabolism in patients with PA. Awareness and treatment of this pre-diabetic or diabetic state are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.